GNCA
Genocea Biosciences, Inc. [GNCA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GNCA Stock Summary
In the News
GNCA Financial details
Company Rating
Neutral
Market Cap
0
Income
-39.27M
Revenue
270K
Book val./share
0.17
Cash/share
0.28
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
08 Mar 2023
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
0
P/FCF
-
Quick Ratio
1.99
Current Ratio
2.24
Debt / Equity
1.25
LT Debt / Equity
0.68
-
-
EPS (TTM)
-0.56
EPS next Y
-
EPS next Q
-
EPS this Y
-76.6%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-116.45%
EPS Q/Q
9.52%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.53%
Inst Trans
0.07%
ROA
-28%
ROE
-86%
ROC
-1.4%
Gross Margin
100%
Oper. Margin
-3174%
Profit Margin
-940%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-4-1.45
52W High
-
52W Low
-
RSI
-
Rel Volume
0.38
Avg Volume
80.57K
Volume
30.27K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-85.71%
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0001
Change
-85.71%
GNCA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0.03 | 0.02 | |
| Net income per share | -15.86 | -2.69 | -1.89 | -0.94 | -0.22 | |
| Operating cash flow per share | -13.31 | -4 | -1.83 | -0.89 | -0.66 | |
| Free cash flow per share | -13.64 | -4.02 | -1.88 | -0.95 | -0.71 | |
| Cash per share | 3.43 | 2.55 | 1.94 | 1.71 | 0.54 | |
| Book value per share | -1.69 | 0.71 | 1.21 | 0.19 | 0.39 | |
| Tangible book value per share | -1.69 | 0.71 | 1.21 | 0.19 | 0.39 | |
| Share holders equity per share | -1.69 | 0.71 | 1.21 | 0.19 | 0.39 | |
| Interest debt per share | 4.48 | 1.54 | 0.75 | 0.54 | 0.15 | |
| Market cap | 4.15M | 2.96M | 42.73M | 112.66M | 79.55M | |
| Enterprise value | 6.19M | -8.58M | 17.13M | 56.76M | 53.53M | |
| P/E ratio | -0.07 | -0.11 | -1.1 | -2.58 | -5.16 | |
| Price to sales ratio | 0 | 0 | 0 | 82.9 | 48.47 | |
| POCF ratio | -0.09 | -0.07 | -1.13 | -2.7 | -1.75 | |
| PFCF ratio | -0.09 | -0.07 | -1.1 | -2.55 | -1.63 | |
| P/B Ratio | -0.69 | 0.4 | 1.71 | 12.54 | 2.94 | |
| PTB ratio | -0.69 | 0.4 | 1.71 | 12.54 | 2.94 | |
| EV to sales | 0 | 0 | 0 | 41.77 | 32.62 | |
| Enterprise value over EBITDA | -0.12 | 0.33 | -0.46 | -1.38 | -1.56 | |
| EV to operating cash flow | -0.13 | 0.21 | -0.45 | -1.36 | -1.18 | |
| EV to free cash flow | -0.13 | 0.21 | -0.44 | -1.28 | -1.1 | |
| Earnings yield | -13.67 | -9.4 | -0.91 | -0.39 | -0.19 | |
| Free cash flow yield | -11.76 | -14.01 | -0.91 | -0.39 | -0.61 | |
| Debt to equity | -2.37 | 2.02 | 0.58 | 2.66 | 0.41 | |
| Debt to assets | 0.82 | 0.48 | 0.28 | 0.24 | 0.2 | |
| Net debt to EBITDA | -0.04 | 0.45 | 0.69 | 1.36 | 0.76 | |
| Current ratio | 0.83 | 2.52 | 6.62 | 3.29 | 2.24 | |
| Interest coverage | -32.41 | -38.71 | -41.21 | -34.05 | 46.47 | |
| Income quality | 0.84 | 1.48 | 0.97 | 0.95 | 1.37 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 10.59 | 8.97 | |
| Research and developement to revenue | 0 | 0 | 0 | 24.99 | 23.78 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.01 | 0.03 | 0.06 | 0.07 | |
| Capex to revenue | 0 | 0 | 0 | -1.9 | -2 | |
| Capex to depreciation | -0.78 | -0.22 | -1.03 | -2.27 | -2.11 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 1.45 | 2.22 | |
| Graham number | 24.57 | 6.56 | 7.18 | 2.02 | 1.41 | |
| ROIC | -6.72 | -2.6 | -0.87 | -1.21 | -0.52 | |
| Return on tangible assets | -3.24 | -0.89 | -0.74 | -0.44 | -0.28 | |
| Graham Net | -3.15 | 0.25 | 0.61 | -0.21 | 0.12 | |
| Working capital | -2.7M | 16.33M | 35.3M | 57.23M | 23.14M | |
| Tangible asset value | -6.05M | 7.34M | 25.04M | 8.98M | 27.08M | |
| Net current asset value | -10.46M | 3.28M | 14.02M | -7.28M | 12.93M | |
| Invested capital | -2.37 | 2.02 | 0.58 | 2.66 | 0.41 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 3.28M | 2.59M | 1.11M | 543.5K | 517K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 9.37 | -3.79 | -1.56 | -4.87 | -0.57 | |
| Capex per share | -0.33 | -0.02 | -0.05 | -0.06 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2022-03-31 for Q1
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.02 | -0.02 | 0 | |
| Net income per share | -0.18 | -0.06 | -0.05 | -0.21 | -0.23 | |
| Operating cash flow per share | -0.19 | -0.15 | -0.16 | -0.16 | -0.21 | |
| Free cash flow per share | -0.2 | -0.17 | -0.17 | -0.17 | -0.23 | |
| Cash per share | 1 | 0.89 | 0.7 | 0.53 | 0.28 | |
| Book value per share | 0.03 | 0.06 | 0.54 | 0.38 | 0.17 | |
| Tangible book value per share | 0.03 | 0.06 | 0.54 | 0.38 | 0.17 | |
| Share holders equity per share | 0.03 | 0.06 | 0.54 | 0.38 | 0.17 | |
| Interest debt per share | 0.3 | 0.29 | 0.27 | 0.13 | 0.22 | |
| Market cap | 179.29M | 159.05M | 134.03M | 81.67M | 88.9M | |
| Enterprise value | 132.9M | 117.9M | 103.97M | 55.65M | 84.25M | |
| P/E ratio | -3.74 | -9.22 | -9.25 | -1.35 | -1.37 | |
| Price to sales ratio | 0 | 0 | 81.68 | -49.77 | 329.26 | |
| POCF ratio | -14.47 | -15.13 | -11.8 | -7.35 | -5.85 | |
| PFCF ratio | -13.28 | -14.17 | -11.27 | -6.78 | -5.5 | |
| P/B Ratio | 101.75 | 39.22 | 3.54 | 3.02 | 7.18 | |
| PTB ratio | 101.75 | 39.22 | 3.54 | 3.02 | 7.18 | |
| EV to sales | 0 | 0 | 63.36 | -33.91 | 312.03 | |
| Enterprise value over EBITDA | -11.74 | -32.23 | -35.43 | -3.65 | -5.49 | |
| EV to operating cash flow | -10.72 | -11.22 | -9.15 | -5.01 | -5.54 | |
| EV to free cash flow | -9.84 | -10.5 | -8.74 | -4.62 | -5.21 | |
| Earnings yield | -0.07 | -0.03 | -0.03 | -0.19 | -0.18 | |
| Free cash flow yield | -0.08 | -0.07 | -0.09 | -0.15 | -0.18 | |
| Debt to equity | 11.15 | 4.75 | 0.5 | 0.41 | 1.25 | |
| Debt to assets | 0.23 | 0.25 | 0.29 | 0.2 | 0.4 | |
| Net debt to EBITDA | 4.1 | 11.25 | 10.24 | 1.71 | 0.3 | |
| Current ratio | 6.02 | 4.24 | 3.44 | 2.24 | 1.35 | |
| Interest coverage | -44.52 | -51.58 | -40.4 | 6.8 | -68.17 | |
| Income quality | 1.03 | 2.44 | 3.14 | 0.84 | 0.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 2.37 | -1.9 | 13.33 | |
| Research and developement to revenue | 0 | 0 | 5.77 | -6.27 | 46.09 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.09 | 0.07 | 0.05 | 0.08 | 0.06 | |
| Capex to revenue | 0 | 0 | -0.32 | 0.57 | -3.56 | |
| Capex to depreciation | -2.91 | -1.92 | -1.34 | -2.29 | -2.4 | |
| Stock based compensation to revenue | 0 | 0 | 0.63 | -0.62 | 3.34 | |
| Graham number | 0.33 | 0.29 | 0.8 | 1.36 | 0.94 | |
| ROIC | -0.42 | -1.53 | -0.59 | -0.33 | -0.45 | |
| Return on tangible assets | -0.14 | -0.06 | -0.06 | -0.27 | -0.42 | |
| Graham Net | -0.24 | -0.19 | 0.31 | 0.12 | -0.09 | |
| Working capital | 57.4M | 48.08M | 35.91M | 23.14M | 6.38M | |
| Tangible asset value | 1.76M | 4.06M | 37.83M | 27.08M | 12.39M | |
| Net current asset value | -13.36M | -10.42M | 23.53M | 12.93M | -2M | |
| Invested capital | 11.15 | 4.75 | 0.5 | 0.41 | 1.25 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 784K | 1.2M | 1.17M | 739K | 547K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -6.8 | -1.06 | -0.1 | -0.56 | -1.31 | |
| Capex per share | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
GNCA Frequently Asked Questions
What is Genocea Biosciences, Inc. stock symbol ?
Genocea Biosciences, Inc. is a US stock , located in Cambridge of Massachusetts and trading under the symbol GNCA
What is Genocea Biosciences, Inc. stock quote today ?
Genocea Biosciences, Inc. stock price is $0.0001 today.
Is Genocea Biosciences, Inc. stock public?
Yes, Genocea Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 80.57K
- Employee 74
- CEO Mr. William Clark
- Headquarters Cambridge,MASSACHUSETTS,US
- IPO Date 2014-02-05
-
Website
https://www.genocea.com 
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
